MOMA Therapeutics

The post Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight appeared first on MOMA Therapeutics.

The post MOMA-313, an inhibitor of the DNA polymerase theta helicase domain, prevents BRCA reversions in preclinical models appeared first on MOMA Therapeutics.

The post Orally Administered MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors: Phase 1 Study Design appeared first on MOMA Therapeutics.

-MEDI First Time Disclosures: Breakthroughs on New Medicines -Wednesday, August 20, 2025, 2 - 6 p.m. -Washington Convention Center, Washington, D.C. -Presenting Author: Dr. Meredeth McGowan, Head of Chemistry -To learn more visit: https://cen.acs.org/phar

- First-in-human study of MOMA-341 focuses on advanced or metastatic solid tumors with high microsatellite instability - - MOMA-341 is a highly differentiated, potentially best-in-class oral covalent Werner helicase inhibitor with a novel chemical scaffol

The post TA repeat expansion outperforms MSI-H as a predictor of sensitivity to the novel WRN inhibitor MOMA-341 appeared first on MOMA Therapeutics.

The post Orally Administered MOMA-313 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Homologous Recombination (HR)-Deficient Tumors: Phase 1 Study Design appeared first on MOMA Therapeutics.

The post TA repeat expansion outperforms MSI-H status as a predictor of sensitivity to the novel WRN inhibitor MOMA-341 appeared first on MOMA Therapeutics.

The post MOMA-313 is a potent and selective inhibitor of the Polθ DNA helicase domain for the treatment of HR-deficient tumors appeared first on MOMA Therapeutics.

CAMBRIDGE, Mass., April 17, 2025 - MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced three poster presentations at the 2025 American Association for Cancer